CSL's $11.7B buyout hits antitrust delay — is it a sign of what's to come?
CSL’s mammoth Vifor Pharma buyout will have to wait a few more months, the company revealed on Wednesday, as experts wonder whether antitrust regulators will slow things down across the entire industry.
While CSL previously expected to close its $11.7 billion Vifor acquisition this June, the company said on Wednesday that the regulatory approval process is taking a bit longer than expected. Some antitrust authorities have approved the transaction, but others remain outstanding, Vifor said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.